William Wierda on Treatment of CLL in Young and Elderly Patients
William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
Older patients with CLL tend to have lower tolerance of some chemotherapies than younger patients because they have more illnesses or are taking more medications.
Wierda says that recent trials show promising results of more effective treatments than chemotherapy for CLL.
Wierda adds that patient age will become less relevant as a prognostic factor as new therapies emerge.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
